Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026)
Quarterly results put Income from Continuing Operations at 39344000.0 for Q1 2026, up 6.79% from a year ago — trailing twelve months through Mar 2026 was 151787000.0 (up 19.48% YoY), and the annual figure for FY2025 was 154651000.0, up 13.03%.
Mineralys Therapeutics has reported Income from Continuing Operations over the past 5 years, most recently at 39344000.0 for Q1 2026.
- Income from Continuing Operations reached 39344000.0 in Q1 2026 per MLYS's latest filing, down from 32235000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6479000.0 in Q2 2022 and bottomed at 56332000.0 in Q3 2024.
- Median Income from Continuing Operations over the past 5 years was 31509000.0 (2024), compared with a mean of 27853764.71.
- The largest annual shift saw Income from Continuing Operations tumbled 240.62% in 2023 before it skyrocketed 34.43% in 2025.
- Over 5 years, Income from Continuing Operations stood at 9073000.0 in 2022, then plummeted by 168.82% to 24390000.0 in 2023, then crashed by 100.73% to 48958000.0 in 2024, then skyrocketed by 34.16% to 32235000.0 in 2025, then dropped by 22.05% to 39344000.0 in 2026.
- Business Quant data shows Income from Continuing Operations for MLYS at 39344000.0 in Q1 2026, 32235000.0 in Q4 2025, and 36936000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | -39.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.34 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -36.94 Mn |
| Jun 30, 2025 | -43.27 Mn |
| Mar 31, 2025 | -42.21 Mn |
| Dec 31, 2024 | -48.96 Mn |
| Sep 30, 2024 | -56.33 Mn |
| Jun 30, 2024 | -41.02 Mn |
| Mar 31, 2024 | -31.51 Mn |
| Dec 31, 2023 | -24.39 Mn |
| Sep 30, 2023 | -22.76 Mn |
| Jun 30, 2023 | -12.14 Mn |
| Mar 31, 2023 | -12.61 Mn |
| Dec 31, 2022 | -9.07 Mn |
| Sep 30, 2022 | -6.68 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -7.57 Mn |